{"id":"lama-laba","safety":{"commonSideEffects":[{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Palpitations"},{"rate":null,"effect":"Dry mouth"},{"rate":null,"effect":"Nasopharyngitis"}]},"_chembl":{"chemblId":"CHEMBL1346","moleculeType":"Small molecule","molecularWeight":"426.56"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"LAMAs block muscarinic M3 receptors on airway smooth muscle, reducing acetylcholine-induced bronchoconstriction. LABAs activate beta-2 adrenergic receptors, increasing cAMP and promoting smooth muscle relaxation. The combination provides complementary bronchodilation through two distinct pathways, improving lung function and reducing symptoms in obstructive airway disease.","oneSentence":"LAMA/LABA is a dual bronchodilator combining a long-acting muscarinic antagonist and long-acting beta-2 agonist to relax airway smooth muscle and improve airflow.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:18:08.846Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic obstructive pulmonary disease (COPD)"},{"name":"Asthma (in some LAMA/LABA formulations)"}]},"trialDetails":[{"nctId":"NCT06786767","phase":"","title":"Fixed Triple Inhaled Combination in Asthmatic Patients in a Real-life Setting","status":"COMPLETED","sponsor":"Chiesi Bulgaria","startDate":"2025-02-01","conditions":"Asthma, Asthma Patients, Asthma Bronchiale","enrollment":281},{"nctId":"NCT07073950","phase":"PHASE4","title":"A Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-11-24","conditions":"Chronic Obstructive Pulmonary Disease, Hyperinflation","enrollment":56},{"nctId":"NCT06040086","phase":"PHASE3","title":"Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2023-09-22","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":1454},{"nctId":"NCT05862545","phase":"","title":"Outcomes in Real-life After Initation of Treatment With Trixeo (Budesonide / Glycopyrronium / Formoterol)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2023-06-01","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":250},{"nctId":"NCT05742802","phase":"PHASE3","title":"Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO).","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2023-03-06","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":1713},{"nctId":"NCT07393685","phase":"","title":"Effectiveness of Xuanfei Jiangzhuo Decoction for Influenza-Induced AECOPD","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University","startDate":"2026-08-01","conditions":"Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Influenza, Human, Virus Diseases","enrollment":300},{"nctId":"NCT06897748","phase":"PHASE2","title":"A Study to Investigate Efficacy and Safety of Tozorakimab Injections Compared With Placebo in Adult Participants With Symptomatic Chronic Obstructive Pulmonary Disease (COPD) With a History of COPD Exacerbations and Elevated Eosinophils","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2025-04-12","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":98},{"nctId":"NCT07051707","phase":"NA","title":"Evaluating the Safety and Efficacy of dNerva Lung Denervation System in Patients With COPD","status":"RECRUITING","sponsor":"Nuvaira, Inc.","startDate":"2026-02-15","conditions":"COPD, Chronic Obstructive Pulmonary Disease","enrollment":200},{"nctId":"NCT03963167","phase":"","title":"Triple Therapy in Real-life: Impact on Adherence and Health Status (TRITRIAL)","status":"COMPLETED","sponsor":"Chiesi Italia","startDate":"2019-08-21","conditions":"COPD","enrollment":661},{"nctId":"NCT07406048","phase":"","title":"Real-World Effectiveness of a Triple Combination BDP/FF/GB Extrafine in a Single Pressurised Metered Dose Inhaler in Brazilian COPD Patients","status":"NOT_YET_RECRUITING","sponsor":"Chiesi Farmaceutica Ltda.","startDate":"2026-01-30","conditions":"COPD (Chronic Obstructive Pulmonary Disease)","enrollment":396},{"nctId":"NCT07372521","phase":"","title":"Measuring Small-Airways Disease Improvement After Step-up to Extrafine TRIple or High-dose ICS/LABA in Patients Uncontrolled on Medium Dose ICS/LABA eXploring T2 Inflammation","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Ioannina","startDate":"2026-01-19","conditions":"Asthma","enrollment":130},{"nctId":"NCT05776927","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma.","status":"NOT_YET_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2026-05-29","conditions":"Asthma","enrollment":304},{"nctId":"NCT04481555","phase":"PHASE4","title":"Eosinophil-guided Reduction of Inhaled Corticosteroids","status":"COMPLETED","sponsor":"Chronic Obstructive Pulmonary Disease Trial Network, Denmark","startDate":"2021-06-28","conditions":"COPD, Inhaled Corticosteroid, Azithromycin","enrollment":444},{"nctId":"NCT05166889","phase":"PHASE3","title":"Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2022-01-03","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":1132},{"nctId":"NCT05158387","phase":"PHASE3","title":"Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations.","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2022-02-07","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":1172},{"nctId":"NCT07329946","phase":"NA","title":"Immuno-inflammatory Response of Erdosteine in COPD","status":"NOT_YET_RECRUITING","sponsor":"Pierachille Santus, MD, PhD","startDate":"2026-02-28","conditions":"COPD","enrollment":30},{"nctId":"NCT05292053","phase":"PHASE4","title":"Outcomes of Once-Daily ICS/LABA/LAMA + PRN Respiratory Therapy Treatments in Hospitalized Patients With COPD Exacerbations","status":"COMPLETED","sponsor":"Baylor Research Institute","startDate":"2022-07-01","conditions":"Copd","enrollment":80},{"nctId":"NCT04718389","phase":"PHASE3","title":"A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-01-26","conditions":"Asthma","enrollment":1719},{"nctId":"NCT06465485","phase":"PHASE3","title":"STEP: Phase IIIb Study of Benralizumab to Step-down Maintenance Therapy in Patients With Severe Eosinophilic Asthma","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2024-02-28","conditions":"Severe Eosinophilic Asthma","enrollment":504},{"nctId":"NCT07192016","phase":"PHASE4","title":"129-Xe MRI Study of Single Triple Therapy Inhaler Effects in COPD Patients With Moderate-severe Dyspnea and/or Poor Health Status With High or Low Risk of Exacerbation","status":"NOT_YET_RECRUITING","sponsor":"Western University, Canada","startDate":"2026-03","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":60},{"nctId":"NCT04902573","phase":"","title":"A Trial Monitoring Therapy Pathways of Asthma Patients Treated With an Extrafine ICS/LABA/LAMA Single-inhaler Triple Therapy in a Real-world Setting and Characterizing the Effects on Health-related Out-comes","status":"COMPLETED","sponsor":"Chiesi UK","startDate":"2021-06-17","conditions":"Asthma","enrollment":147},{"nctId":"NCT05743608","phase":"","title":"NEXThaleR Real-world Study Assessing the EffectivenesS of BDP/FF/G Fixed triPle cOmbiNation on Symptom scorEs in COPD Patients","status":"COMPLETED","sponsor":"Chiesi Hungary Ltd.","startDate":"2023-03-29","conditions":"COPD","enrollment":1336},{"nctId":"NCT07160322","phase":"","title":"Refractory Breathlessness in COPD","status":"RECRUITING","sponsor":"Seoul National University","startDate":"2024-04-11","conditions":"COPD","enrollment":730},{"nctId":"NCT06908421","phase":"","title":"Efficacy of a Smart add-on Device in Combination With a Triple Treatment in Asthma Patients on Inhaler Technique and Adherence","status":"RECRUITING","sponsor":"Chiesi Pharma AB, Nordic","startDate":"2025-09-15","conditions":"Asthma","enrollment":60},{"nctId":"NCT05919394","phase":"PHASE4","title":"Triple vs High Dose Inhaled CORticosteroids","status":"WITHDRAWN","sponsor":"Galaxia Empírica","startDate":"2023-06-01","conditions":"Asthma","enrollment":""},{"nctId":"NCT04651777","phase":"PHASE3","title":"Evaluation of Triple Therapy Using Magnetic Resonance Imaging in Asthma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dr. Grace Parraga","startDate":"2022-08-08","conditions":"Asthma","enrollment":31},{"nctId":"NCT05477108","phase":"PHASE1","title":"Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI With Next-Generation Propellant Compared With BGF MDI With HFA Propellant","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-07-29","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":108},{"nctId":"NCT05569421","phase":"PHASE1","title":"A Study to Assess the Total Systemic Exposure Bioequivalence of of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI With Next-Generation Propellant Compared With BGF MDI With HFA Propellant","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-10-11","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":108},{"nctId":"NCT04053634","phase":"PHASE3","title":"Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2019-08-26","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":689},{"nctId":"NCT04657211","phase":"","title":"Triple Therapy in Chronic Obstructive Pulmonary Disease (COPD) Participants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-01-14","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1212},{"nctId":"NCT06340581","phase":"PHASE1","title":"A Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, & Formoterol (BGF) Metered Dose Inhaler (MDI) With a Next-generation Propellant (NGP) With a Spacer, BGF MDI Hydrofluoroalkane (HFA) With a Spacer, as Well as BGF MDI NGP Without a Spacer","status":"WITHDRAWN","sponsor":"AstraZeneca","startDate":"2024-10-17","conditions":"Healthy","enrollment":""},{"nctId":"NCT06282861","phase":"PHASE4","title":"ANTES B+ Clinical Trial","status":"TERMINATED","sponsor":"Fundacio Privada Mon Clinic Barcelona","startDate":"2024-02-29","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":48},{"nctId":"NCT06297668","phase":"PHASE1","title":"A Study to Assess the Pharmacokinetics and Safety of Budesonide, Glycopyrronium, & Formoterol (BGF) Metered Dose Inhaler (MDI) With a Next-Generation Propellant (NGP) With a Spacer, BGF MDI Hydrofluoroalkane (HFA) With a Spacer, as Well as BGF MDI NGP Without a Spacer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-04-29","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":42},{"nctId":"NCT06841640","phase":"PHASE1, PHASE2","title":"Phase 1/Phase 2a Study of AERO-007 Inhalation Solution, a Nebulized LABA/LAMA Combination for Maintenance Treatment of COPD","status":"COMPLETED","sponsor":"AeroRx Therapeutics Inc.","startDate":"2025-01-15","conditions":"COPD","enrollment":24},{"nctId":"NCT07058259","phase":"NA","title":"Acupuncture for Persistent Dyspnea Despite Medical Treatment in COPD","status":"ACTIVE_NOT_RECRUITING","sponsor":"Istanbul Medeniyet University","startDate":"2024-11-15","conditions":"COPD (Chronic Obstructive Pulmonary Disease), Acupuncture","enrollment":60},{"nctId":"NCT06100042","phase":"","title":"Observational Study on Therapy Pathways of Asthamics Treated With ICS/LABA/LAMA Therapy in a Real-world Setting","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chiesi Italia","startDate":"2024-04-24","conditions":"Asthma","enrollment":200},{"nctId":"NCT07030881","phase":"NA","title":"Effect of Spacer Use on Exacerbation Risk in High-Risk Older Adults With Chronic Airway Diseases Receiving Triple Therapy","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Ningbo University","startDate":"2025-06-20","conditions":"Asthma, COPD","enrollment":380},{"nctId":"NCT04664491","phase":"NA","title":"Effects of COPD Standardized Management on COPD Exacerbation","status":"RECRUITING","sponsor":"China-Japan Friendship Hospital","startDate":"2023-02-04","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":3456},{"nctId":"NCT06460493","phase":"PHASE3","title":"Effect of Ensifentrine Treatment on CAT Score","status":"COMPLETED","sponsor":"Verona Pharma plc","startDate":"2024-06-11","conditions":"COPD","enrollment":20},{"nctId":"NCT06552364","phase":"PHASE4","title":"Air Pollution and Inhaled Corticosteroids in COPD","status":"NOT_YET_RECRUITING","sponsor":"University of British Columbia","startDate":"2025-04-01","conditions":"COPD","enrollment":48},{"nctId":"NCT05563675","phase":"PHASE4","title":"Once Daily Long-Acting Muscarinic Antagonists Administered in the Evening for Prevention of Chronic Obstructive Pulmonary Disease Exacerbations Requiring Hospitalization or Death from Any Cause","status":"COMPLETED","sponsor":"Chronic Obstructive Pulmonary Disease Trial Network, Denmark","startDate":"2023-01-27","conditions":"COPD Exacerbation","enrollment":10011},{"nctId":"NCT06772454","phase":"","title":"To Evaluate the Efficacy and Safety of Inhaled Corticosteroids Combined With Bronchodilators and Programmed Death-ligand 1 (PD-L1) Inhibitor Plus Platinum-based Chemotherapy in Patients With Advanced Lung Squamous Cell Carcinoma Complicated With Chronic Obstructive Pulmonary Disease (COPD)","status":"RECRUITING","sponsor":"Guangzhou Institute of Respiratory Disease","startDate":"2023-01-01","conditions":"Lung Cancer Squamous Cell, COPD","enrollment":60},{"nctId":"NCT06360393","phase":"","title":"Inhaler Adherence and Inhalation Technique Assessed by a Smart Spacer in Patients with Severe Asthma on Biologics","status":"RECRUITING","sponsor":"University Medical Center Groningen","startDate":"2024-05-01","conditions":"Asthma","enrollment":110},{"nctId":"NCT03639051","phase":"NA","title":"Evaluation of the Safety and Efficacy of TLD in Patients with COPD","status":"ACTIVE_NOT_RECRUITING","sponsor":"Nuvaira, Inc.","startDate":"2019-05-23","conditions":"COPD","enrollment":464},{"nctId":"NCT06567977","phase":"","title":"TriMaximize: A Multicentre, Prospective, Non-interventional Trial in Asthma Patients","status":"RECRUITING","sponsor":"Chiesi Poland Sp. z o.o.","startDate":"2024-08","conditions":"Asthma","enrollment":60},{"nctId":"NCT05903989","phase":"","title":"Real-World Treatment Patterns and Patient Reported Outcome in COPD (REMIND)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2023-09-11","conditions":"COPD","enrollment":708},{"nctId":"NCT03954132","phase":"","title":"Spiolto® Respimat® (Tiotropium/Olodaterol) Versus Triple Combination Therapy in Everyday Clinical Treatment Practice for Chronic Obstructive Pulmonary Disease (EVELUT®)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2019-06-07","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":469},{"nctId":"NCT04656223","phase":"","title":"Digital Adherence Monitoring of Inhalative Therapy in Real- Life Conditions","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2020-12-17","conditions":"Asthma","enrollment":434},{"nctId":"NCT06126692","phase":"","title":"3TR Asthma Biologics Cohort (ABC) Study","status":"RECRUITING","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2022-01-10","conditions":"Severe Asthma","enrollment":600},{"nctId":"NCT03527927","phase":"NA","title":"sTep dOWn Inhalers in the reAl woRlD","status":"COMPLETED","sponsor":"Hywel Dda Health Board","startDate":"2017-05-17","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":67},{"nctId":"NCT04355546","phase":"","title":"Non-interventional Study Related to Fixed LAMA/LABA/ICS Triple Therapy","status":"COMPLETED","sponsor":"Chiesi UK","startDate":"2020-07-15","conditions":"COPD","enrollment":94},{"nctId":"NCT05728749","phase":"","title":"A Multicentre, Prospective, Non-interventional Trial Monitoring Therapy Pathways of Asthma Patients Treated With an Extra-fine ICS/LABA/LAMA Single-inhaler Triple Therapy in a Real-world Setting and Characterizing the Effects on Health-related Outcomes","status":"UNKNOWN","sponsor":"Chiesi SAS","startDate":"2023-03-03","conditions":"ASTHMA","enrollment":300},{"nctId":"NCT05927155","phase":"PHASE3","title":"Effects of Acute Long-acting Bronchodilation on Oxygenation and Peripheral Ventilation in COPD","status":"COMPLETED","sponsor":"Erasme University Hospital","startDate":"2021-06-15","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":30},{"nctId":"NCT04072887","phase":"PHASE2","title":"Dose-range Finding Efficacy and Safety Study for QBW251 in COPD Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-09-12","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":974},{"nctId":"NCT03489746","phase":"NA","title":"Steroid Withdrawal Intervention in Fife and Tayside","status":"WITHDRAWN","sponsor":"NHS Tayside","startDate":"2018-05-01","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":""},{"nctId":"NCT05748977","phase":"EARLY_PHASE1","title":"Short Acting Agents Vs Long Acting in Frequent Excerbator COPD Patients","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2023-02-20","conditions":"Copd","enrollment":80},{"nctId":"NCT03290287","phase":"","title":"Aclidinium Bromide Post-Authorisation Safety Study to Evaluate the Risk of Cardiovascular Endpoints","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-03-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":26839},{"nctId":"NCT03662711","phase":"PHASE4","title":"Inhaled Long-acting Bronchodilators With or Without Inhaled Glucocorticosteroids for Preventing Hospitalizations and Death in Elderly Patients With Chronic Obstructive Pulmonary Disease","status":"TERMINATED","sponsor":"Università degli Studi di Ferrara","startDate":"2018-11-11","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":843},{"nctId":"NCT02812862","phase":"PHASE4","title":"Cardiac Effects of Spiolto®/Respimat® in Patients With Congestive Heart Failure and COPD","status":"WITHDRAWN","sponsor":"RWTH Aachen University","startDate":"2016-08","conditions":"COPD","enrollment":""},{"nctId":"NCT04011475","phase":"","title":"A Study in Taiwan Based on Medical Records That Looks at the Occurrence of Flare-ups in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Started LABA/LAMA or LAMA Treatment","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2019-12-29","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1617},{"nctId":"NCT03265145","phase":"PHASE4","title":"Assessment In a Real World Setting of the Effect of Inhaled Steroid-based Triple Therapy Versus the Combination of Tiotropium and Olodaterol on Reducing Chronic Obstructive Pulmonary Disease (COPD) Exacerbations [AIRWISE]","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2017-09-20","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":714},{"nctId":"NCT05342558","phase":"PHASE4","title":"Efficacy and Safety of ICS/LABA vs. LAMA/LABA in Patients With Different COPD Phenotypes.","status":"COMPLETED","sponsor":"National Institute of Respiratory Diseases, Mexico","startDate":"2017-09-19","conditions":"COPD","enrollment":133},{"nctId":"NCT04172701","phase":"","title":"A Study in South Korea Using Medical Records to Look at Different Treatments for Chronic Obstructive Airway Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2020-04-15","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":9284},{"nctId":"NCT02948959","phase":"PHASE3","title":"Evaluation of Dupilumab in Children With Uncontrolled Asthma","status":"COMPLETED","sponsor":"Sanofi","startDate":"2017-04-21","conditions":"Asthma","enrollment":408},{"nctId":"NCT04611633","phase":"","title":"Study in COPD Patients Evaluating the Quality of Life (TRISNOOZE)","status":"TERMINATED","sponsor":"Chiesi SA/NV","startDate":"2021-01-18","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":14},{"nctId":"NCT05145894","phase":"","title":"Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device","status":"UNKNOWN","sponsor":"Healthy Networks","startDate":"2021-09-30","conditions":"Asthma, COPD","enrollment":200},{"nctId":"NCT04184297","phase":"","title":"Comparative Effectiveness and Safety of Tiotropium and Olodaterol in Comparison to Triple Therapy","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2019-11-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":27190},{"nctId":"NCT03158311","phase":"PHASE3","title":"Study to Compare QVM149 and Free Triple Combination of Salmeterol/Fluticasone + Tiotropium","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-02-05","conditions":"Asthma","enrollment":1426},{"nctId":"NCT03219866","phase":"PHASE4","title":"Nebulizer Versus Dry Powdered Inhalers for Chronic Obstructive Pulmonary Disease (COPD)","status":"TERMINATED","sponsor":"Wake Forest University Health Sciences","startDate":"2017-10-03","conditions":"COPD, COPD Exacerbation","enrollment":40},{"nctId":"NCT03250689","phase":"PHASE2","title":"Randomized Study Evaluating the Effect of Danirixin on Neutrophil Extracellular Traps (NETs) in Chronic Obstructive Pulmonary Disease (COPD)","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2017-11-15","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":19},{"nctId":"NCT04737655","phase":"PHASE4","title":"Non-inferiority Evaluation of Trimbow in Critically Ill Patients Admitted in ICU Compared to Standard of Care","status":"UNKNOWN","sponsor":"PARZIBUT Gilles","startDate":"2021-02-15","conditions":"COPD Exacerbation","enrollment":200},{"nctId":"NCT03645434","phase":"PHASE2","title":"A Single Inhalation Dose Study to Assess Efficacy, Pharmacokinetics (PK), Safety and Tolerability of AZD8871 in Patients With Long-term Lung Diseases.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2018-10-10","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":73},{"nctId":"NCT03114969","phase":"","title":"Comparative Study of Error Rates Between ELLIPTA® Dry Powder Inhaler (DPI) and Other DPIs","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-06-08","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":450},{"nctId":"NCT02147015","phase":"NA","title":"Personalized Variable Versus Fixed Dose Glucocorticoid Therapy in AECOPD","status":"COMPLETED","sponsor":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","startDate":"2014-06","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":248},{"nctId":"NCT03467425","phase":"PHASE4","title":"INTREPID: Investigation of TRELEGY Effectiveness: Usual Practice Design","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-04-11","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":3109},{"nctId":"NCT04509661","phase":"PHASE4","title":"Efficacy and Safety of Inhaled Bronchodilator in Non-CF Bronchiectasis With Airflow Limitation","status":"UNKNOWN","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2020-09-01","conditions":"Bronchiectasis Adult","enrollment":200},{"nctId":"NCT03543176","phase":"","title":"Chronic Obstructive Pulmonary Disease (COPD) Dual Therapy Burden of Illness","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-05-31","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":789},{"nctId":"NCT04456205","phase":"","title":"Inhaled Corticosteroid Withdrawal in Chronic Obstructive Pulmonary Disease (COPD)","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2019-10-01","conditions":"COPD, Inhaled Corticosteroid","enrollment":200},{"nctId":"NCT03949842","phase":"PHASE4","title":"Legend: TRELEGY Real World Chronic Obstructive Pulmonary Disease (COPD) Effectiveness Study","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2019-06-27","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":""},{"nctId":"NCT02488590","phase":"","title":"Systematic Approach for the Diagnosis and Treatment of Obstructive Lung Diseases","status":"UNKNOWN","sponsor":"KU Leuven","startDate":"2015-07","conditions":"Chronic Obstructive Pulmonary Disease, Asthma, Overlap Syndrome","enrollment":180},{"nctId":"NCT02850185","phase":"NA","title":"Adjuvant Therapy for Severe COPD Patients in the Stable Phase by an Oxyhydrogen Generator With Nebulizer","status":"UNKNOWN","sponsor":"Shanghai Asclepius Meditec Inc.","startDate":"2016-07-15","conditions":"COPD","enrollment":170},{"nctId":"NCT04000451","phase":"NA","title":"A Therapy for Improving Symptoms in Patients With Acute Exacerbations of COPD by Hydrogen-Oxygen Generator With Neburlizer.","status":"COMPLETED","sponsor":"Shanghai Asclepius Meditec Inc.","startDate":"2019-01-07","conditions":"Copd Exacerbation Acute","enrollment":108},{"nctId":"NCT03724877","phase":"","title":"Effectiveness of Triple Therapy in COPD","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2018-11-10","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":8853},{"nctId":"NCT01794780","phase":"PHASE4","title":"A 1-year Multi-center, Prospective, Cohort Study in Patients With Chronic Obstructive Pulmonary Disease Treated With Long-acting Bronchodilator","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-02-05","conditions":"COPD","enrollment":2229},{"nctId":"NCT04000958","phase":"NA","title":"PIFR-based Inhalation Therapy in Patients Recovering From AECOPD","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2019-09-01","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":460},{"nctId":"NCT02546297","phase":"PHASE4","title":"Comparisons of Inhaled LAMA or LAMA+LABA or ICS+LABA for COPD With Bronchiectasis","status":"UNKNOWN","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2017-09-15","conditions":"COPD, Bronchiectasis","enrollment":90},{"nctId":"NCT03376295","phase":"","title":"Comparative Effectiveness of COPD Treatments","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2017-12-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":3954},{"nctId":"NCT02971293","phase":"PHASE2","title":"Efficacy, Pharmacokinetics (PK), Safety and Tolerability Study of Inhaled AZD8871","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2016-12-15","conditions":"Chronic Obstructive Pulmonary Disease COPD","enrollment":42},{"nctId":"NCT02720757","phase":"","title":"Assessment of Physical Functioning and Handling of Spiolto Respimat in Patients With COPD (OTIVACTO)","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2016-08-26","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":132},{"nctId":"NCT02537691","phase":"PHASE4","title":"Longitudinal Cohort Study in Participants With Severe Asthma to Assess Biomarkers","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2015-08-28","conditions":"Asthma","enrollment":483},{"nctId":"NCT01985334","phase":"PHASE4","title":"Study to Evaluate the Efficacy and Safety of Glycopyrronium or Indacaterol Maleate and Glycopyrronium Bromide Fixed-dose Combination Regarding Symptoms and Health Status in Patients With Moderate COPD Switching From Treatment With Any Standard COPD Regimen","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-02-14","conditions":"COPD","enrollment":4389},{"nctId":"NCT02814656","phase":"PHASE1","title":"Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of AZD8871 in Healthy Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2016-06-22","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":24},{"nctId":"NCT02552160","phase":"","title":"DETECT-Register DocumEnTation and Evaluation of a COPD Combination Therapy","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-09-24","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":3732},{"nctId":"NCT02675517","phase":"","title":"Assessment of Physical Functioning and Handling of Spiolto® Respimat® in Patients With Chronic Obstructive Pulmonary Disease (COPD) Requiring Long-acting Dual Bronchodilation in Routine Clinical Practice","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2016-01-13","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1737},{"nctId":"NCT01937390","phase":"","title":"Observational Study of Adherence to LABA / LAMA in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2011-11-06","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":645},{"nctId":"NCT03504527","phase":"NA","title":"Efficiency of Budesonide Combined With Formoterol and Tiotropium in the Treatment of Acute Exacerbation of ACO","status":"UNKNOWN","sponsor":"Huashan Hospital","startDate":"2018-05-01","conditions":"Asthma-COPD Overlap","enrollment":120},{"nctId":"NCT02451540","phase":"PHASE2","title":"Evaluation of the Effect of Roflumilast in Hyperinflated COPD Patients Using Functional Respiratory Imaging","status":"TERMINATED","sponsor":"FLUIDDA nv","startDate":"2015-09","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":13},{"nctId":"NCT03333018","phase":"","title":"A Drug Utilisation Post-authorisation Study of New Users of Aclidinium Bromide (Monotherapy or in Combination)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-07-06","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":22155},{"nctId":"NCT02796651","phase":"PHASE2","title":"Formoterol Dose Ranging Study (ACHIEVE Duaklir USA Phase IIb)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2016-06-30","conditions":"Chronic Obstructive Pulmonary Disease - COPD","enrollment":132},{"nctId":"NCT01772134","phase":"PHASE3","title":"Efficacy and Safety of the Addition of Fluticanse Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide (62.5 or 125mcg) Once-daily Over 12 Weeks","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-01-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":617}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":301,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["GSK573719+GW642444","umeclidinium (GSK573719) / vilanterol (GW642444)","Anoro ELLIPTA"],"phase":"phase_3","status":"active","brandName":"LAMA/LABA","genericName":"LAMA/LABA","companyName":"Queen's University","companyId":"queen-s-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"LAMA/LABA is a dual bronchodilator combining a long-acting muscarinic antagonist and long-acting beta-2 agonist to relax airway smooth muscle and improve airflow. Used for Chronic obstructive pulmonary disease (COPD), Asthma (in some LAMA/LABA formulations).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}